Elisabeth Genevieve Klompenhouwer

Dr. Elisabeth Genevieve Klompenhouwer


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FBF. E. Buisman
F. E. Buisman
MHM. Y. V. Homs
M. Y. V. Homs
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
WFW. F. Filipe
W. F. Filipe
RBR. J. Bennink
R. J. Bennink
BKBas Groot Koerkamp
Bas Groot Koerkamp
Recurrences are reported in 70% of all patients after resection of colorectal liver metastases (CRLM), in which half are confined to the liver. Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy aims to reduce the risk of intrahepatic recurrence. A large retrospective propensity score analysis demonstrated that HAIP chemotherapy is particularly effective in patients with low-risk oncological features. The aim of this randomized controlled trial (RCT) --the PUMP trial-- is to investigate the efficacy of adjuvant HAIP chemotherapy in low-risk patients with resectable CRLM. This is an open label multicenter RCT. A total of 230 patients with resectable CRLM without extrahepatic disease will be included. Only patients with a clinical risk score (CRS) of 0 to 2 are eligible, meaning: patients are allowed to have no more than two out of five poor prognostic factors (disease-free interval less than 12 months, node-positive colorectal cancer, more than 1 CRLM, largest CRLM more than 5 cm in diameter, serum Carcinoembryonic Antigen above 200 μg/L). Patients randomized to arm A undergo complete resection of CRLM without any adjuvant treatment, which is the standard of care in the Netherlands. Patients in arm B receive an implantable pump at the time of CRLM resection and start adjuvant HAIP chemotherapy 4–12 weeks after surgery, with 6 cycles of floxuridine scheduled. The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival, hepatic PFS, safety, quality of life, and cost-effectiveness. Pharmacokinetics of intra-arterial administration of floxuridine will be investigated as well as predictive biomarkers for the efficacy of HAIP chemotherapy. In a side study, the accuracy of CT angiography will be compared to radionuclide scintigraphy to detect extrahepatic perfusion. We hypothesize that adjuvant HAIP chemotherapy leads to improved survival, improved quality of life, and a reduction of costs, compared to resection alone. If this PUMP trial demonstrates that adjuvant HAIP chemotherapy improves survival in low-risk patients, this treatment approach may be implemented in the standard of care of patients with resected CRLM since adjuvant systemic chemotherapy alone has not improved survival. The PUMP trial is registered in the Netherlands Trial Register (NTR), number: 7493 . Date of registration September 23, 2018.

17 June 2021 in CardioVascular and Interventional Radiology
Verified
Journal Article
Open access
PDF file
ESE. A. Soykan
E. A. Soykan
BAB. M. Aarts
B. M. Aarts
MLM. Lopez-Yurda
M. Lopez-Yurda
KKK. F. D. Kuhlmann
K. F. D. Kuhlmann
JEJoris I. Erdmann
Joris I. Erdmann
EKElisabeth Genevieve Klompenhouwer
Elisabeth Genevieve Klompenhouwer
This systematic review was conducted to determine factors that are associated with the degree of hypertrophy of the future liver remnant following portal vein embolization. An extensive search on September 15, 2020, and subsequent literature screening resulted in the inclusion of forty-eight articles with 3368 patients in qualitative analysis, of which 18 studies were included in quantitative synthesis. Meta-analyses based on a limited number of studies showed an increase in hypertrophy response when additional embolization of segment 4 was performed (pooled difference of medians = − 3.47, 95% CI − 5.51 to − 1.43) and the use of N-butyl cyanoacrylate for portal vein embolization induced more hypertrophy than polyvinyl alcohol (pooled standardized mean difference (SMD) = 0.60, 95% CI 0.30 to 0.91). There was no indication of a difference in degree of hypertrophy between patients who received neo-adjuvant chemotherapy and those who did not receive pre-procedural systemic therapy(pooled SMD = − 0.37, 95% CI − 1.35 to 0.61), or between male and female patients (pooled SMD = 0.19, 95% CI − 0.12 to 0.50).The study was registered in the International Prospective Register of Systematic Reviews on April 28, 2020 (CRD42020175708).

8 May 2019 in Abdominal Radiology
Verified
Journal Article
Open access
PDF file
TLTim A. Labeur
Tim A. Labeur
JRJurgen H. Runge
Jurgen H. Runge
EKElisabeth Genevieve Klompenhouwer
Elisabeth Genevieve Klompenhouwer
HKHeinz-Josef Klümpen
Heinz-Josef Klümpen
RTR. Bart Takkenberg
R. Bart Takkenberg
ODOtto M. van Delden
Otto M. van Delden
Survival outcomes of patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) are heterogeneous. Measuring the apparent diffusion coefficient (ADC) using diffusion-weighted imaging (DWI) may improve overall survival prediction.

5 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CSCharlotte Schneider
Charlotte Schneider
BVBerlinda Jantina De Wit – Van Der Veen
Berlinda Jantina De Wit – Van Der Veen
SJSanne Marie-Antoinette Jansen
Sanne Marie-Antoinette Jansen
KHKenneth Hergaarden
Kenneth Hergaarden
MTMargot E. T. Tesselaar
Margot E. T. Tesselaar
EKElisabeth Genevieve Klompenhouwer
Elisabeth Genevieve Klompenhouwer
Background/Objectives: Over the past few years, high-dose radioembolization (≥150 Gy) has become widely adopted for the treatment of primary liver cancer, while evidence for its application in hepatic metastases is still limited. The aim of this study was to evaluate the safety and efficacy of high-dose transarterial radioembolization (TARE) in patients with hepatic metastases using resin Yttrium-90 (90Y) microspheres. Methods: In this retrospective analysis, patients who were treated with high-dose TARE for hepatic metastases with 90Y resin microspheres between May 2019 and April 2025 were included. The primary outcomes were treatment efficacy and toxicity assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Treatment efficacy was evaluated based on radiological response according to Response Evaluation Criteria in Solid Tumors version 1.1, time to progression and overall survival (OS). Secondary outcomes included 90Y PET/CT post-treatment voxel-based local deposition model dosimetry and its relations to response. Results: A total of 15 patients were included, with hepatic metastases originating from colorectal cancer (n = 11, 73.3%), neuroendocrine tumor (n = 3, 20%) and breast cancer (n = 1, 6.7%). Seven patients (47.7%) had undergone one or multiple prior loco(regional) liver treatments and 13 (86.7%) patients had prior systemic therapy. The median mean tumor absorbed dose was 160.7 Gy (IQR 127.6–245.0 Gy), and the median normal liver parenchyma dose was 40.3 Gy (IQR 21.7–52.3 Gy). Disease control was achieved in all patients, with partial response in 10 patients (66.7%) and stable disease in 5 patients (33.3%) after 3 months. The median OS was 26.5 months (95% CI 24.5 months to no estimate). Two patients (13.3%) experienced grade 3 laboratory toxicity. No grade 4 or 5 toxicities were observed. Conclusions: High-dose TARE with 90Y resin microspheres resulted in a high disease control rate and demonstrated a favorable safety profile, even in this heavily pretreated cohort.

15 March 2021 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
BAB. M. Aarts
B. M. Aarts
TBTarik Baetens
Tarik Baetens
DCDaniel Corominas
Daniel Corominas
SOS. F. Oudkerk
S. F. Oudkerk
ASA. M. Solouki
A. M. Solouki
FGF. M. Gómez
F. M. Gómez

31 July 2025 in Discover Medicine
Verified
Journal Article
Open access
PDF file
CSCharlotte Schneider
Charlotte Schneider
TBTarik Baetens
Tarik Baetens
MDMarloes van Dongen
Marloes van Dongen
RBRegina Beets-Tan
Regina Beets-Tan
FMFernando Gómez Munõz
Fernando Gómez Munõz
EKElisabeth Genevieve Klompenhouwer
Elisabeth Genevieve Klompenhouwer
Introduction There is an increasing recognition for local strategies in managing metastatic breast cancer. This case report shows the potential role of ablative trans-arterial radioembolization in a patient with liver metastasis. Case presentation A 66-year-old female patient with oligoprogressive breast cancer presented with progressive intra-hepatic disease. She underwent trans-arterial radioembolization with an ablative approach (200 Gy) for liver metastasis in segment VII and VIII. The patient had minimal side-effects and resumed chemotherapy one month post-treatment. A persisting complete response was achieved after 3 years of follow-up. Conclusion This case report highlights the efficacy of ablative trans-arterial radioembolization in treating liver metastases from breast cancer.